PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the Craig-Hallum 15th Annual Alpha Select Conference. The event will take place on November 19, 2024, in New York, NY. Company management will be available for investor meetings during the conference. Interested investors are advised to contact conference representatives directly to schedule meetings.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato la sua partecipazione alla 15a Conferenza Annuale Alpha Select di Craig-Hallum. L'evento si terrà il 19 novembre 2024, a New York, NY. La direzione dell'azienda sarà disponibile per incontri con gli investitori durante la conferenza. Gli investitori interessati sono invitati a contattare direttamente i rappresentanti della conferenza per programmare gli incontri.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en fase avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado su participación en la 15ª Conferencia Anual Alpha Select de Craig-Hallum. El evento tendrá lugar el 19 de noviembre de 2024, en Nueva York, NY. La dirección de la empresa estará disponible para reuniones con inversores durante la conferencia. Se aconseja a los inversores interesados que se comuniquen directamente con los representantes de la conferencia para programar reuniones.
PolyPid (Nasdaq: PYPD)는 수술 결과 개선에 집중하는 후기 단계의 생명공학 회사로, 크레이그-할럼 제15회 연례 알파 셀렉트 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 11월 19일에 뉴욕에서 열릴 예정입니다. 회사 경영진은 컨퍼런스 기간 동안 투자자와의 미팅을 위해 대기할 것입니다. 관심 있는 투자자는 미팅 일정을 잡기 위해 컨퍼런스 대표에게 직접 연락할 것을 권장합니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la 15e Conférence Annuelle Alpha Select de Craig-Hallum. L'événement se déroulera le 19 novembre 2024, à New York, NY. La direction de l'entreprise sera disponible pour des réunions avec les investisseurs pendant la conférence. Les investisseurs intéressés sont invités à contacter directement les représentants de la conférence pour planifier des réunions.
PolyPid (Nasdaq: PYPD), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase mit dem Fokus auf die Verbesserung von Operationsergebnissen, hat seine Teilnahme an der 15. jährlichen Alpha Select-Konferenz von Craig-Hallum angekündigt. Die Veranstaltung findet am 19. November 2024 in New York, NY, statt. Das Management des Unternehmens wird während der Konferenz für Investoren-Meetings zur Verfügung stehen. Interessierte Investoren werden gebeten, sich direkt an die Vertreter der Konferenz zu wenden, um Meetings zu planen.
- None.
- None.
PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York, NY.
Investors interested in meeting with PolyPid should contact the conference representative directly.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid (PYPD) participating in the Craig-Hallum Alpha Select Conference?
How can investors meet with PolyPid (PYPD) management at the Craig-Hallum conference?
What type of company is PolyPid (PYPD)?
Where will the Craig-Hallum conference featuring PolyPid (PYPD) be held?
